Lenvatinib

BNF:
Immune system and malignant disease
Status:
Red
Decision Date:
None
 

Comments

RED:

  • NICE TA498 Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (decision date - February 2018)
  • NICE TA535 - Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (decision date  - September 2018
  • NICE TA551: for untreated advanced hepatocellular carcinoma (decision date - January 2019)
  • NICE TA858 - Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma. NHSE commissioned. (Decision date - February 2023)

 

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app